Matthew F Challman
About Me
Matthew Challman is an MD/PhD candidate at the Icahn School of Medicine at Mount Sinai whose research focuses on neuroimmune mechanisms driving neurodegeneration, with an emphasis on how microglial functional states respond to Alzheimer’s disease amyloid pathology. In the Schaefer Lab, he has identified molecular pathways, including CD28 expression on microglia and Polycomb Repressive Complex 2-dependent regulation of TREM2 signaling, that shape microglial interactions with amyloid plaques. This work was supported by a Ruth L. Kirschstein NRSA (F30) fellowship. He plans to pursue residency training in neurology and a career as a physician-scientist dedicated to advancing the understanding and treatment of neurodegenerative disorders.
Language
English
Position
GRADUATE STUDENT | Graduate Students
Multi-Disciplinary Training Areas
Neuroscience [NEU]
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Dr. CHALLMAN has not yet completed reporting of Industry relationships.
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.